Audent Global Asset Management LLC Lowers Stock Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Audent Global Asset Management LLC reduced its stake in iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) by 15.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,998 shares of the financial services provider’s stock after selling 353 shares during the quarter. Audent Global Asset Management LLC’s holdings in iShares Biotechnology ETF were worth $262,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Bradley Foster & Sargent Inc. CT raised its stake in iShares Biotechnology ETF by 5.0% in the fourth quarter. Bradley Foster & Sargent Inc. CT now owns 10,435 shares of the financial services provider’s stock valued at $1,370,000 after purchasing an additional 495 shares in the last quarter. Brevan Howard Capital Management LP purchased a new position in shares of iShares Biotechnology ETF during the fourth quarter worth approximately $5,252,000. Alerus Financial NA purchased a new position in shares of iShares Biotechnology ETF during the fourth quarter worth approximately $205,000. Marathon Capital Management raised its stake in shares of iShares Biotechnology ETF by 2.5% during the fourth quarter. Marathon Capital Management now owns 4,115 shares of the financial services provider’s stock worth $540,000 after acquiring an additional 100 shares in the last quarter. Finally, Osterweis Capital Management Inc. purchased a new position in shares of iShares Biotechnology ETF during the fourth quarter worth approximately $44,000. 58.02% of the stock is owned by hedge funds and other institutional investors.

Get iShares Biotechnology ETF alerts:

iShares Biotechnology ETF Price Performance

IBB stock opened at $131.35 on Wednesday. iShares Biotechnology ETF has a one year low of $104.29 and a one year high of $138.74. The company’s 50 day moving average price is $129.84 and its two-hundred day moving average price is $128.96.

iShares Biotechnology ETF Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 13th. Shareholders of record on Thursday, June 8th were paid a dividend of $0.0062 per share. This represents a $0.02 annualized dividend and a dividend yield of 0.02%. The ex-dividend date of this dividend was Wednesday, June 7th.

iShares Biotechnology ETF Profile

(Get Rating)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More

• Get a free copy of the StockNews.com research report on iShares Biotechnology ETF (IBB)
• As Peloton Shares Fall Over 90%, A Comeback Strategy Surges
• Inflation, The Fed, And The Summer Rally 
• How to Trade Stocks Online the Right Way
• SentinelOne Stock is Down, But Is it Out?
• Oracle Has Spoken: The AI Cloud Is Bigger And Growing Faster

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.